Clinical Trial Search

Primary: Number of Participants With Presence of Donor Lymphohematopoietic Chimerism (Defined as at Least 50% Donor Cells in the Peripheral Blood) in Peripheral Blood by Day +100…

Primary: Progression Free Survival (PFS) — 8.2; 5.6 Months — p=0.012

Primary: Intraoperative Visual Field Assessment — 3.3; 4.3; 3.3; 4.2 units on a scale

Primary: Percentage of Patients With Dose Limiting Toxicity During the First Treatment Cycle in Phase Ia Part of the Study — 0; 0; 0; 0 Percentage of participants

Primary: Mean Cmax Pharmacokinetic Parameter- Part I — 66.3 ug/mL

Primary: Percentage Change in Positive Left Ventricular (LV) dP/dt Max (mm HG/Sec) of Multispot LV Pacing Configuration Compared to Normal Biventricular Pacing — 28.38; 28.58…

Primary: Part A: Number of Serious Adverse Events and Adverse Events Leading to Withdrawal — 0; 0; 0; 0 adverse events

Primary: Gestational Sac Expulsion With One Treatment Dose on Day 3 (Visit 2) and no Need for Additional Medical or Surgical Intervention Within 30 Days of Treatment. — 100; 124…

Primary: Number of Participants With An Improvement in Vision, as Measured by an Increase of 15 Letters on the Early Treatment Diabetic Retinopathy Study (EDTRS) Vision Chart…

Primary: Weight Change (kg) — -1.06; 0.07 kilograms — p=<0.05

Primary: Pre-therapy/Pre-procedure Stress Level Measured by Blood Pressure — 121.9; 121.9; 127.3; 77.2 mmHg

Primary: Accuracy of Blood Pressure Measurement by Sphygmo Relative to the Clinical Standard. — 125.3; 85.2; 129.8; 76.9 mmHg

Primary: Area Under the Plasma Concentration-time Curve From Time of Dose Extrapolated to Infinite Time (AUC[0-infinity]) of DTG for Part 1 — 58900; 58400 hours*nanograms/mL…

Primary: Incidence Rate of Adverse Events (AE) — 11.99 Percentage of patients (%)

Primary: Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic…